atherothrombotic microembolization, 7, 8 inflammation, 8, 9 activation of neutrophils, and platelets, 8 which cause releasing of oxygen-free radicals, proteolytic enzymes, and proinflammatory mediators that can cause tissue and endothelial damage, particularly in critically injured myocytes. 10 In addition, coronary microvascular spasm and reperfusion injury, 11 as well as genetic predisposition, 10 may play a part in the pathophysiology of no-reflow phenomenon. No-reflow phenomenon is indisputably associated with poor short-and longterm clinical outcomes and may negate the potential benefits of primary PCI in patients with STEMI. 12, 13 Early detection of no-reflow phenomenon, which may occur within 1-2 hours after completion of PCI, is essential because it is associated with reduced myocardial salvage, larger infarct size, and increased 5-year mortality. 14 Clinically, it may present as recurrent angina, cardiogenic shock, arrhythmia, or acute dyspnea compatible with pulmonary edema secondary to heart failure.
Autoimmunity has been considered to contribute to atherosclerosis. In fact, it seems that both cellular and humoral immune systems are involved in the development and progression of atherosclerosis. 15 Several studies have demonstrated autoimmunityrelated microvascular dysfunction caused by increased sympathetic outflow, 16 increased oxidative stress, 17 increased endothelin-1 levels, 18 and reduced bioavailability of nitric oxide in response to shear stress. Nevertheless, coronary flow reserve, which has been considered as a useful diagnostic index for both functional and physiologic assessment of coronary circulation, 19 has been demonstrated to be impaired in several autoimmune diseases, including systemic sclerosis, 20 and rheumatoid arthritis (RA). 21 Rheumatoid factor (RF), an antibody against the Fc portion of immunoglobulin G, has been implicated to have an association with atherosclerosis. Rheumatoid factor is observed not only in RA, but also in other rheumatic and inflammatory diseases, including Sjogren's syndrome, systemic lupus erythematosus, and polydermatomyositis. In addition, positive reactions of RF can be observed in up to 5% and in up to 25% of healthy young and elderly population, respectively. Rheumatoid factor is associated not only with an increased likelihood of developing coronary artery disease but also with an increased cardiovascular mortality in healthy subjects. 22 Although the association between autoimmunity and no-reflow phenomenon has not been addressed in the literature, these patients demonstrate increased rates of poor coronary flow after elective and primary PCIs. 23 The aim of this study was to evaluate the relationship between baseline serum RF levels and no-reflow phenomenon in patients with acute STEMI undergoing primary PCI.
| ME THODS

| Study population and design
This single-center, cross-sectional study included a total of 318 consecutive patients (267 male and 51 female; mean age:
55.8 ± 9.9 years) who were diagnosed with acute STEMI and underwent primary PCI at our clinic within 12 hours of onset of All patients were given a therapy of 300 mg acetylsalicylic acid and a loading dose of clopidogrel prior PCI. They also received angiotensin-converting enzyme inhibitor, beta-blocker, statin, and heparin. Glycoprotein IIb/IIIa antagonists were not given to any patient prior PCI.
The study was conducted in accordance with the Declaration of Helsinki. An institutional ethics committee approved the study protocol and each participant provided a written informed consent.
| Identification of cardiovascular risk factors
Data concerning cardiovascular risk factors, including age, gender, hypertension (HT), diabetes mellitus (DM), hyperlipidemia (HPL), and smoking status, were noted. Patients who were previously on oral antidiabetic and/or insulin therapy or those with fasting blood glucose, measured at least twice, ≥126 mg/dL were considered diabetic.
24
Patients who were previously on antihypertensive therapy or those with blood pressures, measured at least twice, ≥140/90 mmHg were considered hypertensive. 25 The presence of HPL was considered when a measure of total cholesterol >200 mg/dL or low-density lipoprotein cholesterol (LDL-C) > 100 mg/dL was obtained or when the patient was previously on lipid-lowering medication in accordance with the "Adult Treatment Panel III" guideline. 26 Patients who were using tobacco products on admission to hospital and those who had quit smoking within the past month were considered smokers.
| Diagnosis of acute ST-segment elevation myocardial infarction
Diagnosis 
| Transthoracic echocardiographic examination
Each patient underwent transthoracic echocardiographic examination before discharge. Examinations were performed with the patient lying in the supine position or in the left decubitus position.
Measurements were obtained in accordance with the recommendations of the American Echocardiography Unit. Left ventricular ejection fraction (LVEF) was calculated according to Simpson's method.
| Coronary angiography and no-reflow phenomenon
Index coronary angiography procedures were performed using commercially available Siemens (Axiom Sensis XP, Berlin, Germany) device via the femoral approach. Informed consents were obtained routinely from all of the patients before the procedure. Primary PCI of the IRA was performed using standard conventional techniques.
The diagnosis of no-reflow phenomenon was defined as a flow of TIMI II or less without the presence of dissection, mechanical obstruction, significant residual stenosis, or other plausible causes. Elecsys, Roche Diagnostics, Mannheim, Germany). were fulfilled or not. The correlation between variables was performed using the Spearman's rank-order correlation analysis. All significant parameters (P < .1) in the univariate analysis were selected for the multivariate model, and forward conditional logistic regression analysis was used to determine the independent predictors of no-reflow phenomenon. Odds ratio and 95% confidence interval of each independent variable were calculated. A two-tailed P value of <.05 was considered significant. 
| Statistical analysis
TA B L E 1 Baseline characteristics of the patients
| RE SULTS
This study included a total of 318 consecutive patients who were diagnosed with acute STEMI and underwent primary PCI. Consistent with the published data, no-reflow phenomenon was observed in 13.8% of the patients. Mean age was significantly higher in the no-reflow group than in reflow group (59.3 ± 10.2 vs 55.3 ± 9.7, P = .013). Interestingly, all patients who developed no-reflow were males. Mean BMI was significantly lower in the no-reflow group than in reflow group (26.3 ± 5.5 vs 28.1 ± 4.3, P = .010).
Regarding cardiovascular risk factors, prevalences of HT and DM were significantly lower in no-reflow group than in reflow group (%22.7 vs %38.3, P = .046 for HT; %4.5 vs %28.8, P = .001 for DM).
However, the smoking ratio was significantly higher in the former (%72.7 vs %46.0, P = .001).
Medians of hemoglobin level and leukocyte count were significantly higher in no-reflow group than in reflow group (14.9 Baseline characteristics of the patients are shown in Table 1 .
Angiographic and procedural characteristics of study groups were similar (Table 2) . Age, leukocyte count, platelet count, triglyceride level, HDL cholesterol level, hs-CRP, hs-cTnT, and LVEF were significantly associated with RF level (P < .05) ( Table 3) . (Table 4 ).
| D ISCUSS I ON
The major findings of this study include (i) patients with acute STEMI who developed no-reflow during primary PCI have significantly higher baseline RF levels, and (ii) baseline RF levels are independently associated with the no-reflow phenomenon in these patients. To the best of our knowledge, this is the first report in the literature demonstrating the association between RF concentration and no-reflow phenomenon in patients with acute STEMI undergoing primary PCI.
In the present study, no-reflow was identified by changes in TIMI flow in the epicardial artery, which directly affects myocardial perfusion. Thrombolysis in myocardial infarction flow grade is a crude but accurate indicator for myocardial reperfusion if this is suboptimal (i.e., <3). Myocardial no-reflow carries a poor prognosis and an increased mortality rate. Thus, intraprocedural Predischarge LVEF (%) −0.398 <.001 HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; LVEF, left ventricular ejection fraction. a Spearman's rank correlation coefficient. Thus, increased inflammation in patients with increased RF levels is likely to contribute to no-reflow. Indeed, observations of positive associations of RF with hs-CRP and leukocyte count suggest that RF correlates with inflammation in the study population. An alternative explanation is that RF may directly mediate no-reflow through endothelial injury and microvascular dysfunction. Indeed, it has been previously suggested that atherosclerotic plaques contain immunoglobulins and complements suggesting an immune complex activity 32 and that RF may play a direct pathogenic role in endothelial injury and cardiovascular disease through immune complex formation. [15] [16] [17] [18] 20, 21, 33 Taken together, these data suggest with reflow and no-reflow. In this study, BMI was independently associated with the no-reflow phenomenon.
TA B L E 4 Independent predictors of no-reflow phenomenon
Iwakura et al 39 reported that there was no difference in glycosylated hemoglobin or in the incidence of DM between reflow and no-reflow groups. In addition, Harrison et al 37 also revealed that the incidence of DM between reflow and no-reflow groups was similar.
However, it was previously reported that despite similar high rates of TIMI flow grade 3 after primary PCI in patients with and without DM, patients with DM were more likely to have abnormal myocardial perfusion. 40 Unlike previous studies, DM was independently associated with the no-reflow phenomenon in this study.
In the present study, patients who developed no-reflow had significantly higher median SYNTAX score I. Moreover, this score was an independent predictor of myocardial no-reflow in these patients.
Magro et al 41 revealed that SYNTAX score was an independent predictor of myocardial no-reflow in patients with STEMI and that a score >21 carries a double risk for developing no-reflow. Şahin et al 36 reported similar findings.
Taken together with the published data, this study raises the importance of the potential role of autoimmunity in the pathophysiology of coronary circulation and no-reflow phenomenon. However, it did not determine the exact mechanism of RF in the pathogenesis of this phenomenon.
| LIMITATI ON S OF THE S TUDY
This was a single-center study which included a relatively small sample size. A multicenter study involving more patients could have more significant results and data. Some diseases may have not been recognized in the study group. Only angiographic parameters were used in determining no-reflow. However, the microcirculation was not directly evaluated, for example, by contrast echocardiography.
ST-segment resolution as another measure of no-reflow was not available in all patients. 
| CON CLUS ION
